vulnerable period Archives - Drugs in Context

Home vulnerable period

Corrigendum: Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts

José Antonio Magaña Serrano, José Angel Cigarroa López, Adolfo Chávez Mendoza, Juan Betuel Ivey-Miranda, Genaro Hiram Mendoza Zavala, Luis Olmos Domínguez, Sergio Armando Chávez Leal, José Ernesto Pombo Bartelt, Eduardo Heberto Herrera-Garza, Gerardo Mercado Leal, Rodolfo Parra Michel, Luisa Fernanda Aguilera Mora, Patricia Lenny Nuriulu Escobar

Article Type

Corrigendum

Published

26 Mar 2024

The authors wish to make the following corrections to their article: Magaña Serrano JA, Cigarroa López JA, Chávez Mendoza A, Ivey-Miranda JB, Mendoza Zavala GH, Olmos Domínguez L, Chávez Leal SA, Pombo Bartelt JE, Herrera-Garza EH, Mercado Leal G, Parra Michel R, Aguilera Mora LF, Nuriulu Escobar PL. Corrigendum: Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts. Drugs Context. 2024;13:2023-8-1. https://doi.org/10.7573/dic.2023-8-1

Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts

Article Type

Review

Published

16 Jan 2024

Heart failure (HF) represents a major healthcare problem, reaching epidemic figures worldwide. This article provides an update on the vulnerable period of HF with reduced ejection fraction (HFrEF) and recommendations are given regarding the management of HF during this phase.